Abstract This review provides an update on current developments with prevention, treatment, and cure strategies in the field of pediatric HIV. There has been tremendous progress in the prevention and treatment of pediatric HIV infection. With new strategies for prevention of mother-to-child transmission,
Introduction
There has been tremendous progress in the prevention and treatment of pediatric HIV infection. In well-resourced settings, comprehensive prevention of mother-to-child transmission of HIV (PMTCT) efforts has resulted in few new perinatal infections ( However, despite improving ART coverage, only 22 % of HIV-infected children are currently receiving treatment [4] , and a staggering number of childhood deaths, 190,000 [170,000-220,000] in 2013, continue to be attributed to HIV infection [7] . Furthermore, large numbers of adolescents are newly acquiring HIV, and HIV has become the secondleading cause of death among adolescents globally (Fig. 2) [8]. This review outlines the progress toward prevention, treatment, and cure in the field of pediatric HIV.
Prevention of Mother-to-Child HIV Transmission
The number of new pediatric infections globally continues to decrease with 240,000 [210,000-280,000] children less than 15 years of age newly acquiring HIV in 2013 ( Fig. 1 ) [4] . Improved access to HIV testing and ART along with better implementation of PMTCT services has likely contributed to this decline. Option B? has provided a simplified PMTCT approach [9] with increasing evidence supporting its impact on improving maternal access to ART and retention across the PMTCT cascade. However, complex challenges to long-term retention of mothers and their infants throughout the period of MTCT risk are being described. There is also a growing body of research examining the potential adverse effects of in utero ART exposure, and the cumulative evidence is increasingly reassuring.
Option B1: Uptake and Retention Along the PMTCT Cascade
One of the most notable recent developments in PMTCT globally has been the introduction of lifelong ART for all pregnant and breastfeeding women, the Option B? approach [9] . Option B? (B?) emerged at a time when there were significant losses along the PMTCT cascade due to the complexity of determining which pregnant women needed ART for their own health from those who required only ARV prophylaxis for PMTCT (Options A and B) [10] . Option B? simplified the PMTCT implementation strategy by introducing a test and treat approach and reframing PMTCT as lifelong treatment for all pregnant and breastfeeding women, thereby improving access to ART and reducing opportunities for dropout along the cascade. However, retention of women and infants within PMTCT services remains problematic. A recent study from Malawi (where Option B? was first introduced) using aggregate data from 540 health facilities (n = 21,939) and patient-level data from 19 facilities (n = 11,534) found that loss-to-follow-up (LTFU) at 6 months was 17 % among women starting ART under Option B?. Moreover, compared to women who initiated ART for their own health, women who started ART in PMTCT services were five times more likely not to return to clinic [OR 5.0 Studies examining these losses reveal the complexity of retaining mothers and babies in HIV services and the myriad of inter-related factors that influence outcomes including health facility and patient-level factors, as well as patient-provider relations and quality of counseling.
A study from southeastern Malawi [16 • ] examined the relationship between models of service delivery at 141 health facilities and retention among pregnant women initiating ART. Factors independently associated with ART retention were district location, patient volume, and the model of care: facilities where women were referred from the antenatal clinic (ANC) to the ART clinic for initiation and follow-up were five times more likely to have higher retention rates than facilities where women initiated ART in the ANC and were subsequently referred to ART clinic for follow-up [adjusted odds ratios (aOR) 5.4(1. [20] found that after controlling for other factors, the odds of adhering to Option B? PMTCT were 4.7 times higher among women who received medication counseling as compared to those who did not (aOR 4.7, 95 % CI 1.98-11.35). Much research is currently underway exploring how best to optimize uptake and retention along the PMTCT cascade [21-27]. However, much work remains to be done to better understand the complexity of retention, measure long-term retention, and ultimately evaluate impact on MTCT and infant HIV-free survival.
Efficacy and Complications of Antiretroviral Regimens for PMTCT
The use of a once-daily fixed-dose regimen, tenofovir (TDF) ? emtricitabine (FTC) ? efavirenz (EFV) for all adults, including pregnant and breastfeeding women, is an essential component of the Option B? approach in low and middle-income countries [9] . The first evidence of the efficacy of EFV-based ART during pregnancy and breastfeeding was provided by the PROMOTE trial (ClinicalTrials.gov, NCT00993031) conducted in rural Uganda [28 •• ]. Among 389 study participants randomized to one of two ART regimens, the proportion of women with virologic suppression (HIV-1 RNA B400 copies/ mL) at delivery was higher with an EFV-versus lopinavir/ritonavir (LPV/r)-based regimen (97.6 % in the EFV arm and 86.0 % in the LPV/r arm, p \ 0.001) and similar at 48 weeks postpartum (91 and 88.4 % for EFVand LPV/r-based regimens respectively, p = 0.49). HIVfree infant survival was also similar between study arms: 97.2 % (EFV) versus 92.9 % (LPV/r), p = 0.10. Effectiveness under non-trial conditions has not yet been evaluated.
There is also an increasingly large body of research examining the impact to infants of HIV and ARV exposure in utero and through breastfeeding [ However, ongoing vigilance will be important, especially as new drugs are introduced into adult treatment regimens, as there will likely be new fetal exposures as women become pregnant. For example, however, the Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring of ART Toxicities (SMARTT) Study, a prospective observational cohort study of HIV-and ARV-exposed uninfected children, found no association of first-trimester exposures with congenital anomalies for any ARV, combination ARV regimens, or any drug class. However, among protease inhibitors, first-trimester atazanavir (ATZ) was associated with increased risk for skin and musculoskeletal anomalies
In addition to potential ARV-associated toxicities, there are emerging concerns that HIV-exposed uninfected infants may have other vulnerabilities [40 • ]. A recent study demonstrated significantly increased risk of invasive pneumococcal disease and mortality among HIV-exposed compared to unexposed young infants in South Africa [43 • ]. However, many well described, often preventable and easily treated health conditions such as pneumonia, diarrhea, malnutrition, and malaria continue to pose the greatest threats to survival among populations of HIV-exposed, uninfected infants.
Treatment of HIV Infection in Children
Due to the tremendous success of PMTCT efforts, the perinatal pediatric epidemic in high-and many middleincome countries is predominantly adolescent with many already transitioned into adulthood. While there is also a growing population of aging adolescents with perinatal HIV in high burden, low-resource settings, adolescent issues are still often overshadowed by the need to address the still too many [4] new pediatric infections and substantial unmet treatment need. A new global movement aims to close the treatment gap, but evidence to guide approaches to pediatric HIV case finding is very limited. Substantial delays in both diagnosis and treatment of HIV infection among infants and children continue alongside new studies demonstrating the benefit of ART earlier initiation. Among adolescents, large numbers are newly acquiring HIV, and are being recognized as a particularly vulnerable group (Fig. 2) [8]. At the same time, studies determining drug dosing and efficacy of new agents as well as long-and short-term toxicities and complications continue to shape treatment options for children.
The Pediatric Treatment Cascade
Early Infant Diagnosis, Case Finding, ART Initiation, and Retention
Despite improved coverage and uptake of PMTCT, early infant HIV diagnosis (EID) programs continue to underperform. An MMWR report [44 • ] documented results from the EID program in Francistown, Botswana from 2005-2012. Despite being among the most successful PMTCT programs in sub-Saharan Africa, the report identified substantial challenges in the EID program. Almost one third of the 10,923 HIV-exposed infants did not receive a virologic test to determine infection status, and of the 202 infants identified as HIV-infected, only 123 (60 %) initiated ART. Similarly, a study from Malawi reported that in the context of Option B?, only 52 % of 513 HIV-exposed infants were tested at 6-12 weeks [45] . Results from a national assessment of missed EID opportunities in South Africa [46 • ] found that 68 % of immunization clinics provided EID testing for infants with reported or documented HIV exposure but only 9 % offered testing to infants with undocumented/unknown HIV exposure. Finally, a cohort study described HIV-exposed infant out- Beyond infancy, evidence on the most effective strategies to identify and link HIV-infected children to care is scarce [48, 49] , and delays in diagnosis and ART initiation persist. One study from Malawi [50 • ] introduced dedicated community health workers to improve identification and enrollment into care of HIV-infected infants and children by expanding both facility and community-based HIV testing. Following the intervention, there was a sixfold increase in rate of enrollment of children into HIV care from 3.2 to 19.8 per month. Provider-initiated testing and counseling on inpatient wards has been shown to be an effective approach to identify HIV-infected children in high HIV prevalence settings but is rarely implemented routinely. Additional efforts to identify HIV-exposed and infected children and research on the most effective approaches to case finding are warranted.
Timely ART can dramatically reduce morbidity and mortality in HIV-infected children [51] . However, timely ART initiation remains a challenge particularly in countries with the highest burden of pediatric infections [7] . A multistudy collaboration [ Alongside reports of late treatment initiation is a burgeoning body of evidence suggesting the need for earlier treatment across all ages. The CHER study [51] demonstrated that early antiretroviral therapy, started at 6-12 weeks of age, reduced mortality and HIV progression by 75 % [5 • ]. However, a recent study from South Africa suggests that ART initiation by 3 months of age may not adequately prevent disease progression [55 •• ] . The investigators extracted records of all infants started on ART by 3 months of age between June 2007 and September 2010 at 20 public clinics and one large ART hospital service. On logistic regression, each month increase in age at ART initiation lowered the odds of initiating ART in an optimal state (OR 0.56, CI 0.36-0.94) and increased the odds of advanced HIV disease at ART initiation (OR 1.69, CI 1.05-2.71).
Results from several studies are building a case for universal treatment for all HIV-infected children independent of age, CD4 cell count, or viral load. A secondary analysis [56] of data from the ARROW trial, a strategy trial comparing clinical and laboratory monitoring among children on ART, examined patterns of long-term CD4 reconstitution in HIV-infected children starting ART in sub-Saharan Africa. Using nonlinear mixed-effects models, the study found that higher long-term CD4 counts were predicted for children starting ART at younger ages, and with higher CD4 counts (p \ 0.001) suggesting that children who remain ART näıve beyond 10 years of age are unlikely to achieve a normalized CD4 count. Another ARROW analysis demonstrated that delaying ART initiation until older childhood substantially delayed pubertal development and menarche, independent of immunosuppression [57 • ]. These findings suggest that earlier ART initiation may lead to better long-term outcomes among HIV-infected children.
At 
Antiretroviral Treatment Options: Efficacy and Safety
ARV options for children continue to lag behind adults for whom a number of new drug classes and formulations have become available in recent years. However, there is a slowly expanding array of treatment options for pediatric HIV. Once-daily atazanavir (ATV), a protease inhibitor (PI), has been studied down to infancy among both treatment-experienced and naïve children and was shown to be safe and well tolerated with acceptable levels of viral suppression. The Pediatric AIDS Clinical Trials Group 1020A study of ATV [62 • ] enrolled participants from 91 days to 21 years of age, and at week 96 found respective rates of VL suppression of 57.0 % in treatment naïve and 39.3 % in treatment-experienced patients. Raltegravir, an integrase inhibitor (INI), available as a film-coated tablet 400 mg twice daily (6 to \19 years, and C25 kg) and chewable tablet 6 mg/kg (maximum dose 300 mg) twice daily (2 to \12 years), was shown to be well tolerated with favorable virologic and immunologic responses in a multicenter trial [63 • ] of drug-experienced children and is now approved for children 4 weeks of age and older [64] . Once-daily darunavir/ritonavir 800/100 mg, a PI, has been shown to be to be effective and well tolerated for treatment of HIV-1-infected, antiretroviral-naive adolescents (C12 to \18 years) [65 • ]. Dolutegravir, another INI, was the first ARV to receive simultaneous approval in young adolescents and adults [66] . Unfortunately, none of these new drugs are yet widely available in the global marketplace for children.
There is increasing evidence confirming the benefit of starting LPV/r-based ART as first-line therapy in infants regardless of PMTCT history [67 •• , 68] . Unfortunately, in low-resource settings, programs have been slow to incorporate LPV/r into their first-line regimens, and nevirapinebased ART is more often prescribed for infants and young children [69] . This is particularly worrisome in light of new evidence on resistance among ART-naïve HIV-infected children. A study of 230 newly diagnosed children under 2 years of age in South Africa [69] in 2011 found high rates of drug resistance: among the 67.4 % of children with reported PMTCT exposure, 56.8 % had NNRTI and 14.8 % NRTI mutations; of those with no reported or recorded PMTCT exposures, resistance to NNRTI was detected in 24.0 %, NRTI in 10.7 %. It is anticipated that new formulations of LPV/r as sprinkles [70 • ] may improve uptake of PI-based treatment among infants by addressing issues of palatability, storage, transport, and cost.
More information is also becoming available on the long-term safety of ARVs commonly used to treat pediatric HIV infection. The ARROW study found that long-term zidovudine (ZDV)-based ART was associated with similar body circumference and skinfold thickness as abacavirbased ART, with low rates of lipid abnormalities and clinical lipodystrophy [71] . A prospective, open-label study evaluated the efficacy, safety, and pharmacokinetics of TDF (given as TDF/3TC/EFV once daily) in treatmentexperienced children 3-18 years of age in Thailand found no evidence of increased renal glomerular or renal tubular toxicity. However, the investigators reported a statistically significant decrease in spine bone mineral density Z score in the TDF versus non-TDF group [72 • , 73 • ]. A Gilead sponsored trial [74 • ] in the United States, United Kingdom, and Panama randomized HIV-infected children (2 to \16 years) on a stavudine (d4T) or ZDV-containing regimen with HIV-1 RNA\400 copies/mL to continue d4T or ZDV or switch to TDF. In this study, TDF did not demonstrate non-inferiority in maintaining HIV-1 RNA \400 copies/mL at week 48 as compared to d4T or ZDV and 4/79 patients discontinued TDF due to late occurrence (study weeks 84-156) of renal tubular dysfunction.
Additional surveillance for the long term, especially bone effects, of TDF in children is needed [73 • ].
Very Early Treatment and Prospects for CURE
The report of a functional cure in the 'Mississippi baby' brought great optimism to the HIV community. The possibility that very early treatment could result in sustained virologic control off ART (remission) for an infection that necessitates a lifelong commitment to treatment was very compelling. In the case of the 'Mississippi baby,' triple ARV therapy was initiated very close to the time of birth (at 30 h) and discontinued after 18 months of treatment, with no evidence of viral rebound including undetectable proviral DNA, and plasma HIV-1 RNA and HIV-1 antibodies [75] . Unfortunately, more than 2 years after treatment cessation, the period of remission ended, and HIV RNA was detectable at 16,750 copies/mL, dashing hopes that the child may have attained permanent virologic control off ART [76 •• ]. Thus far, additional cases of early treatment have also failed to demonstrate evidence of sustained viral remission off ART. A British child was initiated on triple ARV therapy within hours of life and virally suppressed on treatment for 4 years, but had a rapid viral rebound when ART was temporarily discontinued
Although there has been great disappointment around the failure of early treatment initiators to sustain viral remission off treatment, very early treatment appears to reduce replication-competent HIV-1 reservoir size. Reduction of latent replication-competent HIV reservoirs is believed to be critical to attain a sustained remission [6 • , 78 • , 79 • ]. A report on outcomes of early treated children from three centers in Canada described four vertically infected children with sustained viral suppression on ART [78 • ]. At 2-5 years on treatment, levels of proviral HIV-1 DNA and replication-competent virus in the peripheral blood were dramatically reduced: HIV serology, HIV specific cell-mediated immune response, and ultrasensitive viral load were negative, cell-associated HIV-1 DNA in plasma and virion-associated HIV-1 RNA in stimulated CD4? T cells were undetectable. Only one of two children tested had a low level of replication-competent HIV-1 in CD4? T cells. These findings provide evidence to the hypothesis that early treatment can lead to reduced replication-competent reservoirs. However, treatment interruption is required to determine if any of these children can sustain viral suppression off-treatment and achieve a period of remission. Several studies are currently in progress to examine the impact of very early treatment of the HIVinfected newborns to prevent HIV disease progression, limit and possibly prevent establishment of latent reservoirs, and test approaches to viral eradication [5
Conclusion
There is enormous optimism that the future holds opportunities for more effective prevention, treatment, and possible cure of pediatric HIV infection. With new PMTCT implementation strategies bolstered by robust global support, we are growing ever closer toward elimination of pediatric HIV. PMTCT uptake is being further optimized and there is increasing interest in understanding and addressing challenges with retention. Ongoing vigilance regarding the potential hazards of in utero ART exposure to infants continues with no significant alarms yet identified. Though cure has not been achieved, evidence of the impact of early treatment on reducing HIV-1 reservoir size has enlivened efforts to rapidly identify and treat HIV-infected newborns. There is an increasing array of treatment options and reassuring evidence regarding long-term complications of ART. Unfortunately, alongside burgeoning evidence suggesting the benefit of even earlier treatment, timely identification and treatment of children remains a challenge. Evidence regarding most effective case finding and linkage strategies is urgently needed in addition to an improved understanding of how to engage and retain HIVpositive children and adolescents on treatment. However, further emboldened by recent international commitments, the future is hopeful. 
